Description
PrymaLab · Research use only
Ovagen 20mg Nasal Spray
Ovagen tripeptide (Glu-Asp-Leu), 20 mg in sterile solution in a metered spray bottle
Ovagen nasal spray contains Glu-Asp-Leu, the synthetic EDL tripeptide of 375.4 Da from Vladimir Khavinson’s short-peptide series. The bottle holds 20 mg of Ovagen as a sterile solution in bacteriostatic water, at no more than 0.2% w/v, so there is no powder to dissolve. Research on EDL itself is limited to cell and tissue cultures of kidney cells, while nasal delivery is a separate pharmaceutical field, and none of that work has tested EDL.
Specifications
| Property | Value |
|---|---|
| Compound | Ovagen Glu-Asp-Leu (EDL); Khavinson peptide bioregulator |
| CAS number | Not assigned |
| Molecular formula | C15H25N3O8 |
| Theoretical mass | 375.4 Da |
| Sequence / structure | H-EDL-OH (3 residues; free N- and C-termini) |
| Contents | Ovagen: 20 mg per bottle (≤ 0.2% w/v) |
| Form | Sterile aqueous solution in bacteriostatic water (0.9% benzyl alcohol), supplied in a metered nasal spray bottle |
| Storage, sealed | Store at 2–8 °C, protected from light; do not freeze |
| Safety data sheet | PL-SDS-120 |
What is in the bottle
The bottle contains 20 mg of the same H-EDL-OH tripeptide sold freeze-dried in the Ovagen 20 mg vial, dissolved at or below 0.2% w/v in bacteriostatic water preserved with 0.9% benzyl alcohol. In molar terms that is about 53 µmol, as in the vial. The safety data sheet does not classify the peptide. Benzyl alcohol is listed as harmful by ingestion or inhalation, an eye irritant and a skin sensitiser.
Store the bottle upright with the cap on, at 2 to 8 °C and away from light, and do not let it freeze. General advice on peptide solutions is in peptide storage and stability.
What the research covers
Pharmaceutical interest in the nasal route is general rather than specific to this peptide. Illum’s 2002 review described how drug delivery companies were developing nasal systems for conventional drugs and for peptides, and discussed the finding that some substances travel from the nose to the brain along the olfactory pathway1. The review is about delivery technology. It does not mention EDL or any Khavinson peptide, and none of the EDL papers used the nose.
EDL itself has been studied in culture. The Khavinson group’s kidney work coded it T-35 and reported that, in tissue explants from the kidneys of young and old rats, it stimulated proliferation and reduced apoptosis, less strongly than a calf kidney peptide complex2. In aging primary kidney cell cultures the same group named the gelatinase MMP-14 as its target3. Neither study says anything about how the peptide behaves in a spray solution or whether it crosses a mucous membrane.
The evidence that bears on this format is therefore thin: a small tripeptide, culture data from one group and a delivery literature that has not tested it. The Ovagen peptide guide covers the compound’s wider literature.
How each lot is tested
Every lot is tested in PrymaLab’s own laboratory in Ashland, Kentucky before release: RP-HPLC for purity, LC-MS for identity, Karl Fischer titration for water, LAL for endotoxin and USP <71> for sterility. Published certificates are listed on the results page and can be checked by number and key on the verify page. The certificate covers the peptide lot used to fill the bottle, not the finished solution. These are in-house results from PrymaLab Analytical, not an independent test, and the lab is not accredited to ISO 17025. The third-party testing guarantee on this page still applies: if any independent laboratory finds the wrong compound, or less than the stated purity or amount, the order is refunded and the cost of the test is reimbursed.
Frequently asked questions
Is the spray the same Ovagen as the vial and pen?
Yes. All three contain the synthetic tripeptide Glu-Asp-Leu. The vial is dry powder for storage at −20 °C, while the spray and the pen are ready-made solutions in bacteriostatic water that are kept cold and never frozen. The spray and the vial each hold 20 mg; the pen holds 6 mg.
How concentrated is the solution?
The safety data sheet gives 20 mg of Ovagen per bottle at no more than 0.2% w/v, and the bottle label states the amount. For work that needs a concentration chosen in the lab, the freeze-dried vial supplies a known mass of dry peptide instead.
Has EDL been studied as a nasal spray?
No. None of the EDL papers cited here involved the nasal route; they are culture studies of kidney cells. The nasal delivery review on this page concerns peptides and drugs in general and does not mention EDL.
Is the spray for human use?
No. Ovagen nasal spray is sold only for laboratory research. It has no approval from the FDA or any other authority for human or veterinary use and must not be used in people or animals.
References
- Illum L. Nasal drug delivery: new developments and strategies. Drug Discov Today. 2002;7(23):1184-9. DOI · PubMed
- Chalisova NI, Lin'kova NS, Nichik TE, et al. Peptide Regulation of Cells Renewal Processes in Kidney Tissue Cultures from Young and Old Animals. Bull Exp Biol Med. 2015;159(1):124-7. DOI · PubMed
- Khavinson VKh, Lin'kova NS, Polyakova VO, et al. Peptides regulate expression of signaling molecules in kidney cell cultures during in vitro aging. Bull Exp Biol Med. 2014;157(2):261-4. DOI · PubMed
Research use only
For laboratory research use only. Ovagen 20mg Nasal Spray is not a drug, food, cosmetic or dietary supplement, is not approved by the FDA or any comparable authority for human or veterinary use, and must not be given to people or animals. It is sold to qualified researchers and institutions, and the buyer is responsible for lawful handling and disposal.
Other formats of Ovagen
Ovagen is also stocked as Ovagen 6mg preloaded 3ml pen. Each listing states its own quantity and concentration, and the pen and vial comparison explains what changes between formats.
Reviews
There are no reviews yet.